IP Library Granted Patent US 10,874,689
Granted Patent B2
US 10,874,689 · App. 16/189,578 · Granted Dec 29, 2020

Topically administered strontium-containing complexes for treating pain, pruritis and inflammation

Inventor: Gary S. Hahn (San Diego, CA)
Assignee: Galleon Labs LLC
A61K33/00A61K9/0014A61K31/05A61K31/192A61K31/198A61K31/265A61K33/24A61P17/00A61P17/18A61P29/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,874,689
App. No.
16/189,578
Granted
Dec 29, 2020
Kind
B2
Abstract

Therapeutically-active compositions that combine strontium with at least one additional molecules that increase the overall therapeutic potency of the combination beyond the potency of any of the separate constituents. Specifically, the combinations perform two important functions; (1) they increase the ability of topically-applied strontium to inhibit both acute sensory irritation (e.g., pruritus and pain), redness, swelling and inflammation (collectively defined for purposes of this description, “irritation”) and the chronic irritation that is characteristic of and contributes to the development and maintenance of painful or pruritic neuropathic conditions; and (2) they decrease the strontium activated pathways that are known to enhance the development and maintenance of pain, pruritis and neuropathic conditions.

Claims (20)

1. A method of treating a condition selected from the group consisting of redness, swelling, and inflammation, comprising administering to a subject in need thereof a composition comprising a complex of:

a divalent strontium salt;

a cysteine-based anti-oxidant selected from the group consisting of N-acetyl cysteine, N-acetyl cysteinate, and esters thereof; and

a polyhydroxyphenol selected from the group consisting of gallic acid, caffeic acid, and mixtures thereof;

wherein the cysteine-based anti-oxidant and the polyhydroxyphenol are conjugated together by a thioester bond formed by a sulfhydryl group of the cysteine-based anti-oxidant and a carboxyl group of the polyhydroxyphenol.

2. The method of claim 1 , wherein the polyhydroxyphenol is gallic acid and esters thereof.

3. The method of claim 1 , wherein the divalent strontium salt is selected from the group consisting of strontium chloride, strontium chloride hexahydrate, strontium sulfate, strontium carbonate, strontium nitrate, strontium hydroxide, strontium hydrosulfide, strontium oxide, strontium acetate, strontium glutamate, strontium aspartate, strontium malonate, strontium maleate, strontium citrate, strontium threonate, strontium lactate, strontium pyruvate, strontium ascorbate, strontium alpha-ketoglutarate, and strontium succinate.

4. The method of claim 1 , wherein administering is topically administering.

5. The method of claim 1 , further comprising a polymer.

6. The method of claim 5 , wherein the polymer is selected from the group consisting of polyvinylpyrrolidone, cyclodextrins, carrageenan, alginic acid, xanthan gum, sulfated polysaccharides, pentosane polysulfate, chondroitin sulfate, dextran sulfate and heparin sulfate.

7. A method of treating inflammation, comprising administering to a subject in need thereof a composition comprising a complex of:

a divalent strontium salt;

a cysteine-based anti-oxidant selected from the group consisting of cysteine, N-acetyl cysteinate, N-acetyl cysteine, and esters thereof; and

a polyhydroxyphenol selected from the group consisting of gallic acid, caffeic acid, and mixtures thereof;

wherein the cysteine-based anti-oxidant and the polyhydroxyphenol are conjugated together by a thioester bond formed by a sulfhydryl group of the cysteine-based anti-oxidant and a carboxyl group of the polyhydroxyphenol.

8. The method of claim 7 , wherein the polyhydroxyphenol is gallic acid.

9. The method of claim 7 , wherein the divalent strontium salt is selected from the group consisting of strontium chloride, strontium chloride hexahydrate, strontium sulfate, strontium carbonate, strontium nitrate, strontium hydroxide, strontium hydrosulfide, strontium oxide, strontium acetate, strontium glutamate, strontium aspartate, strontium malonate, strontium maleate, strontium citrate, strontium threonate, strontium lactate, strontium pyruvate, strontium ascorbate, strontium alpha-ketoglutarate, and strontium succinate.

10. The method of claim 7 , wherein administering is topically administering.

11. The method of claim 7 , further comprising a polymer.

12. The method of claim 11 , wherein the polymer is selected from the group consisting of polyvinylpyrrolidone, cyclodextrins, carrageenan, alginic acid, xanthan gum, sulfated polysaccharides, pentosane polysulfate, chondroitin sulfate, dextran sulfate and heparin sulfate.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2020
From: PIKE, JOSEPH D.
To: GALLEON LABS LLC
Reel/Frame 053813/0193 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2020
From: HAHN, GARY S.
To: COSMEDERM BIOSCIENCE, INC.
Reel/Frame 054172/0086 →
COURT ORDER Recorded Sep 16, 2020
From: COSMEDERM BIOSCIENCE, INC.
To: PIKE, JOSEPH
Reel/Frame 053796/0556 →
Continuity (5)
Continuation 15284892 · Oct 4, 2016
Continuation 14493202 · Sep 22, 2014
Continuation 14386731
Provisional Application 61613923 · Mar 21, 2012
Related Publication 20190076469A1 · Mar 14, 2019
Cited By (1)
US 12,636,311